Horigian Viviana E, Marín-Navarrete Rodrigo A, Verdeja Rosa E, Alonso Elizabeth, Perez María A, Fernández-Mondragón José, Berlanga Carlos, Medina-Mora María Elena, Szapocznik José
Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami, Florida, United States of America,
Instituto Nacional de Psiquiatría Ramón de La Fuente, Mexico City, Mexico.
Rev Panam Salud Publica. 2015 Sep;38(3):233-42.
Low- and middle-income countries (LMIC) lack the research infrastructure and capacity to conduct rigorous substance abuse and mental health effectiveness clinical trials to guide clinical practice. A partnership between the Florida Node Alliance of the United States National Drug Abuse Treatment Clinical Trials Network and the National Institute of Psychiatry in Mexico was established in 2011 to improve substance abuse practice in Mexico. The purpose of this partnership was to develop a Mexican national clinical trials network of substance abuse researchers and providers capable of implementing effectiveness randomized clinical trials in community-based settings. A technology transfer model was implemented and ran from 2011-2013. The Florida Node Alliance shared the "know how" for the development of the research infrastructure to implement randomized clinical trials in community programs through core and specific training modules, role-specific coaching, pairings, modeling, monitoring, and feedback. The technology transfer process was bi-directional in nature in that it was informed by feedback on feasibility and cultural appropriateness for the context in which practices were implemented. The Institute, in turn, led the effort to create the national network of researchers and practitioners in Mexico and the implementation of the first trial. A collaborative model of technology transfer was useful in creating a Mexican researcher-provider network that is capable of changing national practice in substance abuse research and treatment. Key considerations for transnational technology transfer are presented.
低收入和中等收入国家（LMIC）缺乏开展严格的药物滥用和心理健康有效性临床试验以指导临床实践的研究基础设施和能力。美国国家药物滥用治疗临床试验网络的佛罗里达节点联盟与墨西哥国家精神病学研究所于2011年建立了合作伙伴关系，以改善墨西哥的药物滥用治疗实践。该合作伙伴关系的目的是建立一个墨西哥药物滥用研究人员和提供者的国家临床试验网络，能够在社区环境中开展有效性随机临床试验。2011年至2013年实施并运行了一种技术转让模式。佛罗里达节点联盟通过核心和特定培训模块、特定角色指导、配对、示范、监测和反馈，分享了在社区项目中开展随机临床试验的研究基础设施开发的“诀窍”。技术转让过程本质上是双向的，因为它基于对实践实施背景下的可行性和文化适宜性的反馈。该研究所反过来牵头努力创建墨西哥研究人员和从业者的国家网络，并开展了首个试验。技术转让的协作模式有助于创建一个能够改变药物滥用研究和治疗国家实践的墨西哥研究人员 - 提供者网络。文中还介绍了跨国技术转让的关键考虑因素。
